Tannin and anti-gliadin antibody compositions for treatment of a disease of the intestinal tract

Abstract

The present invention relates to a composition for use in the treatment of an intestinal tract disorder caused by a gluten-associated protein, said composition comprising at least one agent which binds to the gluten-associated protein, characterized in that the composition is administered at the same time as or at most within 60 minutes after administration of at least one tannin to a patient.

1 .- 27 . (canceled) 
     
     
         28 . A combination preparation suitable for a treatment of a disease of an intestinal tract of a subject, the combination preparation comprising:
 a first dosage form, wherein the first dosage form comprises at least one agent that binds to a gluten-related protein; and   a second dosage form, wherein the second dosage form comprises at least one tannin.   
     
     
         29 . The combination preparation of  claim 28 , wherein the first and the second dosage forms are further defined as oral dosage forms. 
     
     
         30 . The combination preparation of  claim 28 , wherein the agent comprises a protein or polypeptide. 
     
     
         31 . The combination preparation of  claim 28 , wherein the agent is an antibody, an antibody fragment, an aptamer, a designed ankyrin repeat protein, or a specific receptor directed against the gluten-related protein. 
     
     
         32 . The combination preparation of  claim 31 , wherein the agent is an immunoglobulin Y antibody. 
     
     
         33 . The combination preparation of  claim 31 , wherein the agent is a polyclonal antibody from a mammal, a polyclonal antibody from a bird, an antibody from a lizard, a monoclonal antibody, or an antibody from lungfish blood. 
     
     
         34 . The combination preparation of  claim 31 , wherein the agent is an anti-gliadin antibody or a gliadin-binding fragment thereof. 
     
     
         35 . The combination preparation of  claim 28 , wherein the disease of the intestinal tract is caused by a gluten-related protein. 
     
     
         36 . The combination preparation of  claim 28 , wherein the disease of the intestinal tract is a celiac disease. 
     
     
         37 . The combination preparation of  claim 36 , wherein the celiac disease is asymptomatic celiac disease, classical celiac disease, subclinical celiac disease, symptomatic celiac disease, refractory celiac disease, latent celiac disease, potential celiac disease, celiac disease autoimmunity, gluten intolerance, non-celiac gluten sensitivity, or a gluten-associated disorder. 
     
     
         38 . The combination preparation of  claim 28 , wherein the at least one tannin is a gallotannin, catechol tannin, Lamiacea tannin, or algal tannin. 
     
     
         39 . The combination preparation of  claim 28 , further comprising at least one bacterial protease. 
     
     
         40 . The combination preparation of  claim 28 , further comprising prolylendopeptidase. 
     
     
         41 . The combination preparation of  claim 28 , further comprising at least one eukaryotic and/or prokaryotic cell capable of reducing and/or suppressing inflammatory processes in a stomach and/or an intestinal tract. 
     
     
         42 . The combination preparation of  claim 41 , wherein the at least one cell is further defined as a cell of  Flavobacterium  sp.,  Lactobacillus  sp.,  Aspergillus  sp., or  Bifidobacterium  sp. 
     
     
         43 . The combination preparation of  claim 41 , wherein the composition comprises an amount of the at least one cell of 10 9  to 10 14  cells. 
     
     
         44 . The combination preparation of  claim 28 , wherein the combination preparation comprises 10 mg to 10,000 mg of the at least one tannin. 
     
     
         45 . The combination preparation of  claim 28 , wherein the combination preparation comprises 1 mg to 15,000 mg of the at least one agent that binds to a gluten-related protein. 
     
     
         46 . A kit suitable for a treatment of a disease of an intestinal tract, the kit comprising at least one dose of at least one tannin and at least one dose of at least one agent that binds to a gluten-related protein. 
     
     
         47 . The kit of  claim 46 , wherein said doses are further defined as oral doses.